Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 30;26(15):7367.
doi: 10.3390/ijms26157367.

Growth Hormone Therapy in Recurrent Implantation Failure: Stratification by FSH Receptor Polymorphism (Asn680Ser) Reveals Genotype-Specific Benefits

Mihai Surcel  1 , Georgiana Nemeti  1 , Iulian Gabriel Goidescu  1 , Romeo Micu  1 , Cristina Zlatescu-Marton  2 , Ariana Anamaria Cordos  3 , Gabriela Caracostea  4 , Ioana Cristina Rotar  1 , Daniel Muresan  1 , Dan Boitor-Borza  1
Affiliations

Growth Hormone Therapy in Recurrent Implantation Failure: Stratification by FSH Receptor Polymorphism (Asn680Ser) Reveals Genotype-Specific Benefits

Mihai Surcel et al. Int J Mol Sci. .

Abstract

Recurrent implantation failure (RIF) remains a challenging clinical problem. Growth hormone (GH) co-treatment has been explored as an adjunct in poor responders and RIF patients, with inconsistent evidence of benefit. This prospective cohort study assessed the impact of GH supplementation in 91 RIF patients undergoing in vitro fertilization, stratified by FSHR (follicular stimulating hormone receptor) genotype Asn680Ser with or without GH supplementation. Patients were stratified by FSHR genotype into homozygous Ser/Ser versus Ser/Asn or Asn/Asn groups. Overall, GH co-treatment conferred modest benefits in the unselected RIF cohort, limited to a higher cumulative live birth rate compared to controls and elevated leukemia inhibitory factor (LIF) levels (p < 0.05 both). When stratified by FSHR genotype, the Ser/Ser subgroup exhibited markedly better outcomes with GH. These patients showed a higher (0.5 vs. 0.33, p = 0.003), produced more embryos (2.88 vs. 1.53, p = 0.02), and had a markedly improved cumulative live birth rate-50% with GH versus 13% without-highlighting a clinically meaningful benefit of GH in the Ser/Ser subgroup. No significant benefit was observed in Asn allele carriers. These findings suggest that FSHR genotyping may help optimize treatment selection in RIF patients by identifying those most likely to benefit from GH supplementation.

Keywords: FSH receptor; endometrial dysfunction; genotype Asn680Ser; growth hormone; leukemia inhibitory factor; progesterone; recurrent implantation failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
CONSORT diagram of the patient recruitment and allocation process.
See this image and copyright information in PMC

References

    1. Cimadomo D., Craciunas L., Vermeulen N., Vomstein K., Toth B. Definition, diagnostic and therapeutic options in recurrent implantation failure: An international survey of clinicians and embryologists. Hum. Reprod. 2021;36:305–317. doi: 10.1093/humrep/deaa317. - DOI - PubMed
    1. Somigliana E., Vigano P., Busnelli A., Paffoni A., Vegetti W., Vercellini P. Repeated implantation failure at the crossroad between statistics, clinics and over-diagnosis. Reprod. Biomed. Online. 2018;36:32–38. doi: 10.1016/j.rbmo.2017.09.012. - DOI - PubMed
    1. (The Writing Group) for the Participants to the 2022 Lugano RIF Workshop. Pirtea P., Cedars M.I., Devine K., Ata B., Franasiak J., Racowsky C., Toner J., Scott R.T., de Ziegler D., et al. Recurrent implantation failure: Reality or a statistical mirage?: Consensus statement from the July 1, 2022 Lugano Workshop on recurrent implantation failure. Fertil. Steril. 2023;120:45–59. doi: 10.1016/j.fertnstert.2023.02.014. - DOI - PubMed
    1. Hill M.J. Recurrent implantation failure: Sapereaude. Fertil. Steril. 2021;116:1430–1431. doi: 10.1016/j.fertnstert.2021.09.030. - DOI - PubMed
    1. Franasiak J.M., Alecsandru D., Forman E.J., Gemmell L.C., Goldberg J.M., Llarena N., Margolis C., Laven J., Schoenmakers S., Seli E. A review of the pathophysiology of recurrent implantation failure. Fertil. Steril. 2021;116:1436–1448. doi: 10.1016/j.fertnstert.2021.09.014. - DOI - PubMed

LinkOut - more resources